ऑस्ट्रेलिया - अंग्रेज़ी - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fluidra group australia pty ltd - chlorine present as trichloroisocyanuric acid; sodium tetraborate pentahydrate - tablet (inc. pellet, bolus, suppository, capsule) - chlorine present as trichloroisocyanuric acid mineral-chlorine-acid active 630.0 g/kg; sodium tetraborate pentahydrate mineral-boron other 295.0 g/kg - pool chlorine

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

wausau chemical - zinc sulfate monohydrate (unii: ptx099xsf1) (zinc cation - unii:13s1s8sf37) - directions: mix 3-5 gallons of hb zinc supreme with 50 gallons of clean, warm water to create final solution for use in footbaths for cattle. for best results: cattle hooves need to be clean prior to walking through the footbath solution to allow complete and effective contact with the hoof. if conditions exist that cause hooves to be dirty a prewash or rinse bath with hoof bath detergent hoof cleaner conditioner should be used in front of the treatment footbath. solution should be changed after 200 cow passes. use in conjunction with a total hoof care program including proper hoof trimming, attention to cow comfort and sanitation, correct nutrition and proper footbath management. footbath treatments are recommended every other day at a minimum as a good management practice for maintaining healthy hooves.  it is recommended that you switch out active footbath treatment every several weeks to avoid overuse of a single active ingredient.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

wausau chemical - copper (unii: 789u1901c5) (copper - unii:789u1901c5) - copper 19.4 g in 1 l - directions: mix 3 gallons of hb copper supreme with 50 gallons of clean water to create final solution for use in footbaths for cattle. for best results: cattle hooves need to be clean prior to walking through the footbath solution to allow complete and effective contact with the hoof. solution should be changed after 400-600 cow passes. use in conjunction with a total hoof care program including proper hoof trimming, attention to cow comfort and sanitation, correct nutrition and proper footbath management. footbath treatments are recommended every other day at a minimum as a good management practice for maintaining healthy hooves.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

hillestad pharmaceuticals usa - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol succinate, d- (unii: lu4b53jyve) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz - ascorbic acid 100 mg - dialyvite supreme d is a prescription folic acid supplement with additional nutrients indicated for use in improving the nutritional status of renal dialysis patients. this product is contraindicated in patients with known hypersensitivity to any of the ingredients.

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

teleflex medical asia pte. ltd. - anaesthesiology - the lma supreme™ is intended for use in achieving and maintaining control of the airway during routine anaesthesia (fasted patients) and when tracheal intubation fails in non fasted patients during anaesthetic procedures. it is also intended for use in cardiopulmonary resuscitation (cpr) procedures as well as in the ‘failed intubation’ and the ‘cannot-intubate-cannot-ventilate’ situation.

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

asia actual pte. ltd. - cardiovascular - the ht supreme drug coated coronary stent system is indicated for improving the coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length≤35mm) with reference vessel diameters of 2.25 mm to 4.0 mm.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - phentermine hydrochloride 18.6375mg equivalent to phentermine 15 mg - modified release tablet - 15 mg - active: phentermine hydrochloride 18.6375mg equivalent to phentermine 15 mg excipient: cetostearyl alcohol opadry ii (green) 85f210076 magnesium stearate maltodextrin sorbitol stearic acid - indicated as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based on exercise, diet (caloric restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30kg/m² or greater who have not achieved an adequate clinical response to an appropriate weight-reducing regimen alone. may appropriately be initiated in overweight patients with a lower bmi when risk of morbidity from other medical conditions is increased. patients with the following co-morbidities are particular candidates for medical assistance with weight reduction, and may be considered for treatment even if their bmi does not exceed 30 kg/m2: · sleep apnoea · insulin-resistant diabetes mellitus · pre-diabetes or impaired glucose tolerance in association with obesity · high cardiovascular risk status as a consequence of obesity. failure to achieve a weight reduction of 5% within a period of 12 weeks is an indication for discontinuation of treatment. treatment may continue beyond this point provided continued monitoring of the patient occurs (for weight loss and medical conditions) and for as long as weight loss is maintained. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - phentermine hydrochloride 37.275mg equivalent to phentermine 30 mg - modified release tablet - 30 mg - active: phentermine hydrochloride 37.275mg equivalent to phentermine 30 mg excipient: cetostearyl alcohol opadry ii (red) 85f250018 magnesium stearate maltodextrin sorbitol stearic acid - indicated as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based on exercise, diet (caloric restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30kg/m² or greater who have not achieved an adequate clinical response to an appropriate weight-reducing regimen alone. may appropriately be initiated in overweight patients with a lower bmi when risk of morbidity from other medical conditions is increased. patients with the following co-morbidities are particular candidates for medical assistance with weight reduction, and may be considered for treatment even if their bmi does not exceed 30 kg/m2: · sleep apnoea · insulin-resistant diabetes mellitus · pre-diabetes or impaired glucose tolerance in association with obesity · high cardiovascular risk status as a consequence of obesity. failure to achieve a weight reduction of 5% within a period of 12 weeks is an indication for discontinuation of treatment. treatment may continue beyond this point provided continued monitoring of the patient occurs (for weight loss and medical conditions) and for as long as weight loss is maintained. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

homart pharmaceuticals pty ltd - nicotinamide mononucleotide, quantity: 200 mg - capsule, hard - excipient ingredients: calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; magnesium stearate; gelatin; sodium lauryl sulfate; titanium dioxide; allura red ac; quinoline yellow; brilliant blue fcf; purified water

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

homart pharmaceuticals pty ltd - vaccinium macrocarpon, quantity: 108.33 mg (equivalent: vaccinium macrocarpon, qty 65 g) - capsule, hard - excipient ingredients: colloidal anhydrous silica; maltodextrin; magnesium stearate; purified water; gelatin; sodium lauryl sulfate